In this episode of Corruption, Crime and Compliance, Michael Volkov breaks down Veloxis Pharmaceuticals’ more than $46 million settlement with DOJ and HHS-OIG over a years-long kickback scheme involving its kidney transplant drug Envarsus XR, a scheme the DPA says was directed in part by the company’s own former CEO. He examines why Veloxis avoided prosecution and instead secured a deferred prosecution agreement under DOJ’s Corporate Enforcement and Voluntary Self-Disclosure Policy despite executive-level involvement in the misconduct, crediting the company’s disclosure, cooperation, and termination of the responsible executives. The episode also unpacks the financial breakdown across civil, criminal, and Sunshine Act penalties, and closes with a detailed look at the structural compliance overhaul required under Veloxis’s five-year Corporate Integrity Agreement, including a compliance officer mandated to report independently of legal and finance directly to the CEO and board.